Canaccord Genuity upgraded OrganiGram from Hold to Speculative Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/27/2026 | Buy | Canaccord Genuity | |
| 7/17/2024 | Speculative Buy | Canaccord Genuity | |
| 4/15/2024 | Neutral → Buy | Alliance Global Partners | |
| 1/13/2023 | Hold → Buy | Stifel | |
| 1/12/2022 | Hold → Speculative Buy | Canaccord Genuity | |
| 1/12/2022 | $5.70 → $5.30 | Overweight | Cantor Fitzgerald |
| 12/8/2021 | $5.50 → $5.70 | Overweight | Cantor Fitzgerald |
Canaccord Genuity initiated coverage of Organigram Global with a rating of Buy
Canaccord Genuity resumed coverage of OrganiGram with a rating of Speculative Buy
Alliance Global Partners upgraded OrganiGram from Neutral to Buy
6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)
6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)
6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - Europe's licensed cannabis industry is starting to look like one of the most exciting growth stories in the global cannabis market. What was once a fragmented, slow-moving sector is now gaining serious momentum as more countries open up medical cannabis programs, expand patient access, and create clearer licensing frameworks for producers and distributors. Germany continues to lead the charge after its cannabis reforms, but countries like the UK, Portugal, Italy, France, Switzerland, and the Czech Republic are also becoming major pieces of the puzzle. Investors and operators are paying close attention because
Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, is pleased to announce its results for the second quarter ended March 31, 2026 ("Q2 Fiscal 2026" or "Q2"). Q2 FISCAL 2026 HIGHLIGHTS Gross Revenue: $93.3 million (-9% year-over-year). Net Revenue: $59.8 million (-9% year-over-year). International Revenue: $6.1 million (0% year-over-year). Adjusted EBITDA2: $0.9 million (-82% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2 in flower, #2 in pre-rolls, #3 in edibles, and #5 in beverages1. Sanity Group GmbH ("Sanity Group") Acquisition: Subsequent
Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its second quarter fiscal 2026 ended March 31, 2026, on Tuesday, May 12, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, May 12, 2026 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://events.q4inc.com/analyst/574618022?pwd=FVnom6fM To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After regist
Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), is pleased to announce that the shareholders of Organigram have overwhelmingly approved the resolution required to consummate the previously announced acquisition by the Company (the "Transaction") of Sanity Group GmbH ("Sanity Group") and the related private placement financing (the "Private Placement") with BT DE Investments Inc., a wholly-owned subsidiary of British American Tobacco ("BAT") at the Company's annual general and special meeting of shareholders (the "Shareholders") held on March 30, 2026 (the "Meeting"). Shareholders approved an ordinary resolution (the "Transaction Resolution") authorizing (i)
ISS Cites Compelling Strategic Rationale, Favorable Market Reaction, and Strong Institutional Confidence in Recommending Shareholders Vote FOR the Transaction Resolution Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, has recommended that holders of common shares of Organigram ("Shareholders") vote FOR the ordinary resolution (the "Transaction Resolution") to approve the indirect acquisition of Sanity Group GmbH ("Sanity") at the Company's Annual General and Special Meeting of Shareholders (the "Mee
Special Meeting to Approve Acquisition of Sanity Group GmbH Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that it has mailed and filed a management information circular (the "Circular") and related materials (the "Meeting Materials") for its annual and special meeting (the "Meeting") of the holders of its common shares (the "Shareholders") to be held on March 30, 2026. The Circular is available under Organigram's profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. In addition to routine annual business to be conducted, Shareholders at the Meeting will be asked to consider and vote u
Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, is pleased to announce its results for the second quarter ended March 31, 2026 ("Q2 Fiscal 2026" or "Q2"). Q2 FISCAL 2026 HIGHLIGHTS Gross Revenue: $93.3 million (-9% year-over-year). Net Revenue: $59.8 million (-9% year-over-year). International Revenue: $6.1 million (0% year-over-year). Adjusted EBITDA2: $0.9 million (-82% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2 in flower, #2 in pre-rolls, #3 in edibles, and #5 in beverages1. Sanity Group GmbH ("Sanity Group") Acquisition: Subsequent
Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its second quarter fiscal 2026 ended March 31, 2026, on Tuesday, May 12, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, May 12, 2026 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://events.q4inc.com/analyst/574618022?pwd=FVnom6fM To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After regist
Strong year-over-year growth supported by Canadian leadership and growing international sales, improving gross margin. Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, is pleased to announce its results for the first quarter ended December 31, 2025 ("Q1 Fiscal 2026" or "Q1"). Q1 FISCAL 2026 HIGHLIGHTS Gross Revenue: $97.3 million (+46% year-over-year). Net Revenue: $63.5 million (+49% year-over-year). International Revenue: $5.0 million (+51% year-over-year). Adjusted EBITDA2: $5.3 million (+273% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2
SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)
SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)
SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)